---

Related Topics

---

• Patients with chronic kidney disease have a high risk of unfavorable kidney and cardiovascular consequences.

• Researchers do not know the effect of dapagliflozin in patients (with or without type 2 diabetes) with chronic kidney disease.

• Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor indicated for managing diabetes mellitus type 2.

• The study involves 4304 participants with glomerular filtration rate and urinary albumin-to-creatinine ratio assessed.

• The participants were randomly assigned to receive dapagliflozin or placebo.

• The primary outcome was a combination of a sustained reduction in the estimated glomerular filtration rate of at least 50 percent, end-stage kidney disease, or death from renal or cardiovascular disease.

• The trial was stopped because of efficacy.

• Primary outcome event occurred in 197 of 2152 participants in the dapagliflozin group.

• Primary outcome event occurred in 312 of 2152 participants in the placebo group.

• Death occurred in 101 participants in the dapagliflozin group.

• Death occurred in 146 participants in the placebo group.

• The effects of dapagliflozin were similar in participants with type 2 diabetes and in those without type 2 diabetes.

• The study concluded that dapagliflozin is correlated with lower risk of a composite of a sustained decline in the estimated glomerular filtration rate of at least 50 percent, end-stage kidney disease, or death from renal or cardiovascular causes.

Sources:

https://doi.org/10.1056/nejmoa2024816

https://pubmed.ncbi.nlm.nih.gov/19996149

AI Disclosure Statement:
The Chromoscience uses AI-assisted tools to support the preparation and editing of science articles. Content is reviewed by the editor for clarity and consistency with the cited research before publication. Readers are encouraged to consult the original scientific publications for complete findings, methods, and limitations.